Hensing TA - Search Results

1

Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer.

Cella D, Eton D, Hensing TA, Masters GA, Parasuraman B. Cella D, et al. Among authors: hensing ta. Clin Lung Cancer. 2008 Jan;9(1):51-8. doi: 10.3816/CLC.2008.n.009. Clin Lung Cancer. 2008. PMID: 18282359

2

Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.

Hensing TA, Schell MJ, Lee JH, Socinski MA. Hensing TA, et al. Lung Cancer. 2005 Feb;47(2):253-9. doi: 10.1016/j.lungcan.2004.07.040. Lung Cancer. 2005. PMID: 15639724 Clinical Trial.

3

A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.

Gillenwater HH, Stinchcombe TE, Qaqish BF, Tyann M, Hensing TA, Socinski MA. Gillenwater HH, et al. Among authors: hensing ta. Lung Cancer. 2005 Mar;47(3):413-9. doi: 10.1016/j.lungcan.2004.08.009. Lung Cancer. 2005. PMID: 15713525 Clinical Trial.

4

Clinical evaluation and staging of patients who have lung cancer.

Hensing TA. Hensing TA. Hematol Oncol Clin North Am. 2005 Apr;19(2):219-35, v. doi: 10.1016/j.hoc.2005.02.010. Hematol Oncol Clin North Am. 2005. PMID: 15833404 Review.

5

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.

Hensing TA, Hanna NH, Gillenwater HH, Gabriella Camboni M, Allievi C, Socinski MA. Hensing TA, et al. Anticancer Drugs. 2006 Jul;17(6):697-704. doi: 10.1097/01.cad.0000215054.62942.7f. Anticancer Drugs. 2006. PMID: 16917215 Clinical Trial.

6

Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.

Argiris A, Hensing T, Yeldandi A, Patel S, Raji A, Sturgis C, Masters G, Gooding W, Pins M, Kolesar J. Argiris A, et al. J Thorac Oncol. 2006 Jan;1(1):52-60. J Thorac Oncol. 2006. PMID: 17409827 Free article.

7

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.

Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Baggstrom MQ, et al. Among authors: hensing ta. J Thorac Oncol. 2007 Sep;2(9):845-53. doi: 10.1097/JTO.0b013e31814617a2. J Thorac Oncol. 2007. PMID: 17805063 Free article. Review.

8

An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration.

Davis K, Yount S, Del Ciello K, Whalen M, Khan S, Bass M, Du H, Eton D, Masters G, Hensing T, Cella D. Davis K, et al. J Support Oncol. 2007 Sep;5(8):381-7. J Support Oncol. 2007. PMID: 17944147

9

Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy.

Cella D, Wagner L, Cashy J, Hensing TA, Yount S, Lilenbaum RC. Cella D, et al. Among authors: hensing ta. J Natl Cancer Inst Monogr. 2007;(37):53-60. doi: 10.1093/jncimonographs/lgm009. J Natl Cancer Inst Monogr. 2007. PMID: 17951232 Review.

10

Prevalence of poor performance status in lung cancer patients: implications for research.

Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Lilenbaum RC, et al. Among authors: hensing ta. J Thorac Oncol. 2008 Feb;3(2):125-9. doi: 10.1097/JTO.0b013e3181622c17. J Thorac Oncol. 2008. PMID: 18303431 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters